source
- nChroma Bio cuts workforce by half and stops HBV cure trialnChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…
- Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseasesPfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…